» Articles » PMID: 22345666

Neutrophil Extracellular Traps That Are Not Degraded in Systemic Lupus Erythematosus Activate Complement Exacerbating the Disease

Overview
Journal J Immunol
Date 2012 Feb 21
PMID 22345666
Citations 260
Authors
Affiliations
Soon will be listed here.
Abstract

Ongoing inflammation including activation of the complement system is a hallmark of systemic lupus erythematosus (SLE). Antimicrobial neutrophil extracellular traps (NETs) are composed of secreted chromatin that may act as a source of autoantigens typical for SLE. In this study, we investigated how complement interacts with NETs and how NET degradation is affected by complement in SLE patients. We found that sera from a subset of patients with active SLE had a reduced ability to degrade in vitro-generated NETs, which was mostly restored when these patients were in remission. Patients that failed to degrade NETs had a more active disease and they also displayed lower levels of complement proteins C4 and C3 in blood. We discovered that NETs activated complement in vitro and that deposited C1q inhibited NET degradation including a direct inhibition of DNase-I by C1q. Complement deposition on NETs may facilitate autoantibody production, and indeed, Abs against NETs and NET epitopes were more pronounced in patients with impaired ability to degrade NETs. NET-bound autoantibodies inhibited degradation but also further increased C1q deposition, potentially exacerbating the disease. Thus, NETs are a potent complement activator, and this interaction may play an important role in SLE. Targeting complement with inhibitors or by removing complement activators such as NETs could be beneficial for patients with SLE.

Citing Articles

NETosis: A key player in autoimmunity, COVID-19, and long COVID.

Monsalve D, Acosta-Ampudia Y, Acosta N, Celis-Andrade M, Sahin A, Yilmaz A J Transl Autoimmun. 2025; 10:100280.

PMID: 40071133 PMC: 11894324. DOI: 10.1016/j.jtauto.2025.100280.


The emerging role of neutrophil extracellular traps in autoimmune and autoinflammatory diseases.

Zeng L, Xiang W, Xiao W, Wu Y, Sun L MedComm (2020). 2025; 6(3):e70101.

PMID: 40060194 PMC: 11885892. DOI: 10.1002/mco2.70101.


Cell-free DNA: a metabolic byproduct with diagnostic and prognostic potential in rheumatic disorders.

Liu F, Su Y, Liu X, Zhao L, Wu Z, Liu Y Front Pharmacol. 2025; 16:1537934.

PMID: 40008123 PMC: 11850341. DOI: 10.3389/fphar.2025.1537934.


Identification and functional characterisation of a novel DNASE1L3 variant (c.572A>G, p.Asn191Ser) in three Emirati families with systemic lupus erythematosus and hypocomplementaemic urticarial vasculitis.

Aljaberi N, Bharathan A, Gopal R, Mohammed E, Al Shibli F, Tabouni M Lupus Sci Med. 2025; 12(1).

PMID: 39947743 PMC: 11831315. DOI: 10.1136/lupus-2024-001477.


"The NET effect": Neutrophil extracellular traps-a potential key component of the dysregulated host immune response in sepsis.

Retter A, Singer M, Annane D Crit Care. 2025; 29(1):59.

PMID: 39905519 PMC: 11796136. DOI: 10.1186/s13054-025-05283-0.